JAMES F. CIPOLETTI, M.D.; ROBERT B. BUCKINGHAM, M.D., F.A.C.P.; E. LEON BARNES, M.D.; ROBERT L. PEEL, M.D.; KHALID MAHMOOD, M.D.; FRANKLIN E. CIGNETTI, M.D.; JOHN M. PIERCE, M.D.; BRUCE S. RABIN, M.D.; GERALD P. RODNAN, M.D., F.A.C.P.
Thirty-five consecutive patients with progressive systemic sclerosis were prospectively evaluated for evidence of Sjögren's syndrome. Six of the 35 (17%) were judged to have the disorder. This is a higher prevalence than in most reports, but much lower than that recently reported by Alarcón-Segovia and associates (7). An additional 17 of the 35 patients (48%) had significant fibrosis in the absence of sufficient mononuclear cell infiltrates to confirm the diagnosis of Sjögren's syndrome. This group had particularly aggressive scleroderma with serious visceral features, and five died after a short duration of illness. No significant abnormalities were found in biopsies from six patients with the mixed connective tissue disease syndrome, five with Raynaud's phenomenon alone, or in 29 autopsy control subjects who had no evidence of connective tissue disease. Fibrosis in the absence of mononuclear infiltration in minor salivary glands of patients with progressive systemic sclerosis indicates a poor prognosis.
CIPOLETTI JF, BUCKINGHAM RB, BARNES EL, PEEL RL, MAHMOOD K, CIGNETTI FE, et al. Sjögren's Syndrome in Progressive Systemic Sclerosis. Ann Intern Med. ;87:535–541. doi: 10.7326/0003-4819-87-5-535
Download citation file:
Published: Ann Intern Med. 1977;87(5):535-541.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use